Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25608711 | 0.86 | MEN1 (0.52) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL20900404 | 0.85 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL14217283 | 0.85 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL71906 | 0.84 | MEN1 (0.45) | MEN1KMT2ARECQLFAAH | |
| SCHEMBL13805651 | 0.84 | MEN1 (0.45) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL14086890 | 0.82 | KMT2A (0.71) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL21041793 | 0.82 | KDM4E (0.60) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL14644875 | 0.82 | KDM4E (0.60) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL12092856 | 0.82 | MEN1 (0.59) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL21563328 | 0.82 | CASP2 (0.59) | MEN1KMT2ACASP2MAPK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783578-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | MEN1 1868/4885KMT2A 3620/4885CASP2 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.